Acyclovir suppression to prevent recurrent genital herpes at delivery. by Scott, L L et al.
Acyclovir suppression to prevent recurrent genital herpes
at delivery
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Objective: To determine if suppressive acyclovir near term decreased the frequency of clinical recurrences at
delivery in women with recurrent genital herpes simplex virus (HSV) infection.
Methods: We conducted a prospective, double-blind, randomized trial in 234 women with recurrent genital
herpes. Women with genital infection of any frequency were enrolled. Patients received either suppressive oral
acyclovir400 mgthreetimesdailyoranidenticalplaceboafter36 weeks’gestation.Clinicallesionswereidentified,
andHSV cultureswereobtainedat delivery. The frequenciesof clinicaland subclinicalHSV recurrencesat delivery
were evaluated.
Results: Sixpercentofpatientstreatedwithacyclovir,and14% ofpatientstreatedwithplacebohadclinicalHSVat
delivery (p = 0.046). No patients in the acyclovir group had positive HSV cultures, compared with 6% of
placebo-treated patients (p = 0.029). There was no significant difference in subclinical HSV shedding in the
acyclovir group (0%) compared with the placebo-treated group (3%) (p = 0.102).
Conclusions: Suppressiveacyclovir therapy significantly decreasedthe incidence of clinical genital herpes and the
overall incidence of HSV excretion at delivery in patients with previous herpes infection.
Key words: ANTIVIRAL AGENTS; PREGNANCY COMPLICATIONS,INFECTIOUS; HERPES GENITALIS;HERPES
SIMPLEX; CESAREAN DELIVERY
Itisestimated that5%ofthegeneralpopulationhas
a known history of genital herpes1. This creates a
large populationof women knownto beat risk for
transmitting herpes simplex virus (HSV) to their
infants during delivery, should they have a peri-
partum recurrence. To avoid intrapartum HSV
exposure and neonatal infection, it is currently
recommended that pregnant women with visible
genital herpes lesions or prodromal symptoms at
the time of labor have a Cesarean delivery.
Gravidas without visible lesions or prodromal
symptoms should be allowed to continue in labor
because they have a low risk of neonatal HSV
transmission1,2. Using these guidelines, it is esti-
mated that one poor neonatal outcome from
HSV infection is averted for every 1580 Cesarean
deliveries performed for maternal clinical HSV
recurrences3 (at a cost of US$2.5 million).
Suppressive acyclovir therapy decreases the fre-
quencyofclinicalandsubclinicalHSVreactivation
in non-pregnantadults4.A typicalsuppressive dose
in the non-pregnant adult is 400 mg orally, twice
per day5. However, pharmacokinetic studies in
term gravidas have shown that 400 mg orally,
three times daily (t.i.d.) may be necessary to
achieve similar therapeutic serum levels6. We have
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Clinical study 71previously shown that suppressive acyclovir
therapy, given from 36 weeks’ gestation until
delivery, is effective in preventing recurrences of
genital herpes at delivery in patients who experi-
enced their first genital herpes episode in that
pregnancy7. However, the efficacy and safety of
such therapy for patients with genital herpes pre-
dating their pregnancy is unknown. The purpose
of this study was to determine if acyclovir suppres-
sive therapy, administered in the last few weeks of
pregnancy,woulddecreasethefrequencyofsymp-
tomatic genital HSV at delivery in women who
have a history of recurrent genital herpes.
MATERIALS AND METHODS
Eligible patients included any gravida with genital
herpes diagnosed by a viral culture positive for
HSV or by the patient’s recollection of a health
careprovider’sclinical diagnosisbeforethecurrent
pregnancy. Gravidas were eligible for enrollment
withanyfrequencyofrecurrences.Herpessimplex
viral serology was not performed. These criteria
were selected to represent those used in typical
contemporary clinical practice.
Exclusion criteria included serum creatinine
greater than 1.5 mg/dl, immunosuppressive dis-
eases (e.g., HIV infection), a known requirement
for Cesarean delivery (e.g. previous Cesarean with
a classical uterine incision), enrollment in another
study protocol, a gestational age of greater than
36 weeks upon identification, delivery before
36 weeks’ gestation or previous acyclovir intoler-
ance. A patient was considered to be non-compli-
ant if she had not taken any study medication on
each of the seven days immediately prior to deliv-
ery. All subjects with known outcomes were
included in an intent-to-treat analysis.
Patients were recruited from the prenatal clinics
at Parkland Health and Hospital System and
St. Paul Medical Center. Both of these clinic sys-
tems serve a young, indigent population with a
high incidence of sexually transmitted diseases.
Informed consent was obtained from eligible
patients by 36 completed weeks of gestation. At
36 weeks estimated gestational age, a schedule
generated from a random number table was con-
sulted, and women were assigned to receive either
acyclovir 400 mg (GlaxoSmithKline, Research
Triangle Park, NC) or an identical-appearing
placebo, orally, t.i.d until delivery. The acyclovir
and placebo were dispensed in coded bottles, and
the patients and their physicians were blinded to
the study assignment. An individual not involved
with patient care maintained the randomization
list and assigned the study drug group.
Hypothesizing a symptomatic genital herpes
recurrence rate at delivery of 13%8, a 50% decrease
in recurrences at delivery in the treated group,and
an80% power,a sample size of326patientsineach
group (acyclovir and placebo) was projected. The
Foodand DrugAdministration granted an Investi-
gational Drug Number for this protocol; and the
investigational review boards of the University of
Texas Southwestern Medical Center, Parkland
Health and Hospital System and St. Paul Medical
Center granted approval for the study.
The women were evaluated weekly after
36 weeks’ gestation and were questioned at each
visit about genital lesions, prodromal symptoms,
compliance and side effects from the treatment.
Prodromal symptoms were defined as tingling,
itching, or other sensations that the patient typi-
cally related to the onset of her herpes recurrence.
Pill counts were performed at return visits and at
delivery, when possible; and we also relied on
reported compliance. Non-compliance was
definedasnostudy medicationforseven daysprior
to delivery. An examination for genital HSV
lesionswasperformedat eachvisit. Herpescultures
were obtained only if the patient described pro-
dromal symptoms or if a lesion was identified. The
collection, handling and culture technique has
been described previously7,9. Upon presentation
fordelivery, thepatientswereexamined forgenital
lesions and questionedregarding prodromalsymp-
toms. For asymptomatic patients, a combined
herpes culture of the usual lesion site and cervix
was obtained to detect asymptomatic viral shed-
ding. For symptomatic women, any visible genital
or cervical lesions were also cultured for HSV.
Obstetric residents or nurse practitioners that had
been instructed in proper viral culture collection
technique collected the samples from patients
upon their admission to the Labor and Delivery
unit.Studymedications were notcontinuedintra-
partum. Patients were delivered by Cesarean sec-
tion if prodromal symptoms or lesions suspicious
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length of time the amniotic membranes had been
ruptured.Theywereallowedtolaborif prodromal
symptoms and lesions were absent.
The pediatricians were informed of the
mother’s participation in the study, and a physical
exam was performed upon the infant’s admission
to the newborn nursery. Neonatal HSV cultures
were taken from the conjunctiva, oropharynx and
rectum 24–48 hours after delivery; the specimens
were combined in one culture. The infants were
observed for the durationof their routine neonatal
stay for clinical evidence of acyclovir toxicity
(abnormal renal, liver or central nervous system
function)and HSV infection.Prophylacticacyclo-
vir therapy was not administered unless the infant
was thought to have been exposed to an active
herpes lesion. In that case, the decision to initiate
treatment waslefttothediscretion oftheattending
pediatrician. Mothers were instructed to contact
the investigators for any problems in the first
month after discharge, and the infants’ medical
records were reviewed at least one month after
delivery.
Statistical analysis
Statistical analysis included chi-square and two-
tailed Fisher exact tests to evaluate differences
between the acyclovir and placebo treatment
groups. Odds ratios were calculated with 95%
exact confidence limits. A p value less than 0.05
was considered statistically significant. The pri-
mary outcome measured was the frequency of
clinical genital herpes recurrences at delivery.
Secondary outcomes included the frequency of
asymptomatic viral shedding, the frequency of
totalviral shedding,and thefrequencyof Cesarean
delivery for recurrent herpes between the two
groups. All comparisons were done using an
intent-to-treat format. Outcomes were not com-
pared by frequency of recurrences, for there were
too few women with six or more recurrences
annually.
RESULTS
Between February 1, 1992 and January 31, 1998,
234 women with a history of genital herpes were
identified and agreed to participate in the study.
Because only 36% of the anticipated sample size
was enrolled after six years, we felt that an addi-
tional ten years necessary to complete enrollment
was not feasible. Further recruitment was termi-
nated at that time, but patients who had already
enrolled were allowed to complete the study.
Selected maternal and neonatal characteristics
are presented in Table 1. One hundred sixteen
women were randomized to acyclovir and 118
wererandomizedtoplacebo.Twenty-onepatients
in each group did not complete the study. Out-
come information was available for all but three of
these patients (all in the placebo group) who were
lost to follow-up. Differences between the
acyclovir and placebo groups for the various
analyses are presented in Table 2. Two hundred
thirty-one patients with known outcomes were
considered in an intent-to-treat analysis; 116 were
assigned to acyclovir and 115 to placebo. Six
percent (7/116) of the acyclovir-treated patients
had clinically evident genital herpes at the time of
delivery, compared with 14% (16/115) of the
placebo treated patients (p = 0.046). This was a
57% relative decrease in the incidence of clinical
reactivations of genital herpes at the time of
delivery. However, the difference in frequency in
Cesarean delivery between the two groups was
not significant (Table 3).
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Characteristics
Acyclovir
(n = 116)
Placebo
(n = 115)
Ethnicity
Black
White
Hispanic
Other
Age
Parity*
Outbreaks/year
Outbreaks during study
Gestational age at delivery
Birthweight
Five minute Apgar*
Cord pH
40%
31%
28%
1%
24.8
0
2.6
1.1
39.4 weeks
3352 g
9
7.28
47%
31%
20%
1%
24
0
2.6
1.4
39.4 weeks
3401 g
9
7.26
Data presented as percentage, mean, or median* of sample
Table 1 Maternal and neonatal characteristicsTherewasnosignificantdifferencebetweenthe
two groups in the incidence of asymptomatic
(subclinical) HSV shedding at the time of delivery.
There was no significant difference between the
treatment groupsin theincidenceof viral recovery
from clinically apparent lesions. However, when
the total viral recovery (subclinical shedding +
shedding from clinical lesions) was compared,
there was a significant difference between the
treatment groups. None (0/102) of the acyclovir-
treated patients, but 6% (6/102) placebo-treated
patients had virus recovered from the genital tract
at presentation for delivery (p = 0.029).
One infant in the placebo group received
prophylactic acyclovir therapy until his cultures
returned negative. Although the mother had a
Cesarean delivery, she had virus recovered from
lesions on her cervix and labia, and the infant had
transiently elevated liver transaminases after birth.
Ultimately hedidwell. Twootherinfantsfromthe
placebo group whose mothers had genital lesions
but delivered vaginally were observed without
treatment. Their HSV cultures returned negative,
and neither developed any signs of neonatal infec-
tion. No infant in either the acyclovir or placebo
group had clinical evidence of HSV infection,
although one infant born vaginally to a mother
who was not compliant with acyclovir treatment
did have a transiently positive HSV culture. The
mother’sculturestaken atadmission forlaborwere
negative. The infant was observed without treat-
ment, and subsequent HSV cultures were nega-
tive. No other infants experienced any clinically
apparent neurologic, hepatic or renal complica-
tions or other adverse effects attributable to
acyclovir during the neonatal period.
DISCUSSION
In an effort to prevent intrapartum HSV trans-
mission, obstetricians generally resort to Cesarean
delivery when a patient presents for delivery with
recurrent genital herpes lesions or prodromal
symptoms. Under current guidelines, a vaginal
delivery is appropriate in the absence of these
findings1,2. Daily acyclovir therapy suppresses
recurrent genital HSV outbreaks in the non-
pregnant adult4, and it has been suggested that this
treatment be considered as a means to prevent
herpes reactivation at delivery2.
Our study demonstrated that pregnant women
with a history of recurrent genital herpes might
decrease their risk of clinical reactivation at the
time of delivery by more than 50% by using
suppressive acyclovir therapy. These findings are
similar to those reported by Brocklehurst and
colleagues10. These investigators reported a clini-
cally important reduction in the incidence of
herpes lesions present at the time of delivery, but
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Outcome measure at Acyclovir Placebo p value OR [95% CI]
Clinical HSV recurrence
Cesarean for HSV
HSV recovery from lesionsb
Asymptomatic HSV sheddingb
Total HSV viral excretionb
7/116 (6%)
8/116 (7%)
0/5 (0%)
0/97 (0%)
0/102 (0%)
16/115 (14%)
14/115 (12%)
3/16 (19%)
3/86 (3%)
6/102 (6%)
0.046a
0.172a
0.549c
0.102c
0.029c
0.40 [0.13, 1.08]
0.53 [0.19, 1.44]
0 [0, 8.32]
0 [0, 2.13]
0 [0, 0.83]
OR, odds ratio; CL, confidence limits; HSV, herpes simplex virus;
aChi-square analysis, intent-to-treat;
bn is less than total number of
patients since some patients did not have cultures obtained;
cFisher exact test, 2-tailed
Table 2 Differences between acyclovir and placebo groups for various outcome measures, at presentation for
delivery
Indication
Acyclovir
(n = 116)
Placebo
(n = 115)
Repeat
Failure to progress
Malpresentation
Fetal distress
Other
HSV
TOTAL
4
10
3
2
2
8a
29 (25%)
4
10
4
3
0
14b
35 (30%)
aIn a breach of the study protocol, one patient had a Cesarean
delivery for genital herpes without a clinical recurrence at delivery;
bTwo patients with genital lesions inadvertently delivered vaginally
due to rapid delivery and protocol error
Table 3 Indications for Cesarean deliveryterminated the study early due to enrollment diffi-
culties. Unfortunately, the Brocklehurst study did
not have adequate power to rule out a significant
difference.
The significant reduction in clinical herpes
recurrences for our acyclovir treated patients did
not translate into a similar significant reduction in
Cesarean deliveries. Possible explanations include:
the decision to perform a Cesarean delivery based
only on a history of genital herpes (in spite of the
current ACOG recommendations)2, inadvertent
vaginal delivery, and other indications for
Cesarean (such as breech presentation) in addition
to the presence of a herpes lesion (Table 3).
Arecentcost-benefitanalysis wasperformedfor
the use of acyclovir suppression in the last several
weeks of pregnancy. The authors concluded that
suppressive therapywouldcostless, wouldresultin
decreased maternal morbidity and mortality, and
wouldresult in fewer cases of neonatalherpes than
deferring acyclovir treatment and resorting to
Cesarean delivery for clinical reactivations11.
A theoretical concern is whether symptomatic
recurrences would be converted to asymptomatic
shedding episodes by suppressive treatment, thus
potentially increasing an infant’s perinatal expo-
sure to HSV through a vaginal delivery12. The
reported incidence of asymptomatic HSV
shedding at any given time in pregnant women
with genital herpes is about 1–2%13–15. Wald and
colleagues16 reported that acyclovir suppression
decreased asymptomatic shedding by 96% in non-
pregnant patients, but this reduction has not yet
been confirmed in pregnant women. We found
a significant decrease in clinical genital lesions
(14% versus 6%), but no difference in subclinical
shedding (3% versus 0%) in the group treated with
suppressive acyclovir therapy. There was no evi-
dencethatclinical lesions were replacedby asymp-
tomatic shedding.
In fact, acyclovir suppressive therapy signifi-
cantly decreased the total incidence of virus
recovered at presentation for delivery. This has
important implications in that the primary time of
fetal exposure is during the intrapartum period,
regardless of whether the infant is delivered
vaginally or by Cesarean section. The decreased
incidence of viral shedding may decrease the
potential for intrapartum HSV exposure.
On short-term follow-up,there were no appar-
ent adverse effects on any of the neonates whohad
prenatal exposure to acyclovir, 1200 mg daily, at
term. Data from the Acyclovir in Pregnancy
Registry donotsuggest adverse outcomesattribut-
able to acyclovir in over 1200 prenatal exposures,
regardless of gestational age17. Additional anec-
dotal evidence of acyclovir’s safety is provided
indirectlythroughreportedpediatricclinicalexpe-
rience. Both term and preterm infantstreated daily
with intravenous acyclovir tolerate the drug
well18,19. Furthermore, the fetal serum levels in
gravidas taking 1200 mg acyclovir daily have been
reported to be much lower than the acyclovir
levels achieved during neonatal parenteral
treatment6,18,19. However, clinical evaluation is
relatively insensitive toidentifysequelaefromdrug
treatment, and we cannot conclude that prenatal
suppressive acyclovir therapy is completely safe for
the fetus. This study was not designed or powered
to specifically test for newborn safety. Further
evaluation of short- and long-term neonatal out-
comes is necessary. In particular, this should
include the evaluation of the impact of maternal
acyclovir suppression on the fetal and neonatal
kidney.
Thereare some limitations to ourtrial. First, we
did not discriminate between HSV-1 and HSV-2
recurrent genital infections. Since HSV-1 genital
infection tends to reactivate less frequently than
HSV-220, it is possible that the lower frequency of
clinical reactivation in the acyclovir treated
patients was due to an over-representation of
HSV-1-infected patients in the acyclovir group.
However, randomization of the patients should
have resulted in similar numbers of women with
each type of infection in each treatment group. In
fact, the mean annual incidence of clinical herpes
reactivations prior to pregnancy was the same in
each group (Table 1).
Anotherlimitation is the lack of culture-proved
diagnoses in all patients considered eligible for
participation. However, the practicing clinician
often has only the history of the patient to rely on
when making a decision regarding management of
herpesin pregnancy.Ninety percentofadultswith
a clinical picture and history compatible with
first-episode genital herpes had positive culturesin
a recent series21. It is possible that some of these
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havegenital herpes.Randomizationofthepatients
should have resulted in similar numbers of mis-
diagnosed patients in each treatment group.
The main limitation is that our enrollment was
terminated before our planned sample size was
reached. It is possible that early termination intro-
duced bias. However, the number of patients
enrolled is over twice the size of the enroll-
ment in each of the only other two randomized
clinical trials of acyclovir in late pregnancy10,22. In
addition, one of these trials was also halted early
due to low enrollment10.
In summary, acyclovir suppression in the last
several weeks of pregnancy significantly reduced
the incidence of clinically evident genital herpes as
wellastheoverall viral excretion rate at thetime of
delivery in patientswith previous herpesinfection.
We did notobserve any short term, adverse effects
of treatment on the fetus or neonate; however,
further investigation is needed to determine the
safety of antenatal acyclovir exposure.
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